Skip to content Skip to sidebar Skip to footer

Newsletter

Apr 2026

Biotech Stocks Healthcare Stocks Life Sciences

Shares In Dimerix (ASX:DXB) Fell 40% Today; Not About The Data, But About the Timing

Shares in Dimerix fell over 35% this morning and some may think the decline was irrational. After all, the announcement confirmed >90 per cent statistical power for its primary endpoint,…

ByNick Sundich

Apr 2026

Healthcare Stocks Biotech Stocks Growth Stocks Life Sciences

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of…

ByNick Sundich

Jan 2026

Healthcare Stocks

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The two keys to get drugs or devices to market are…

ByNick Sundich

Dec 2025

Uncategorized

Dimerix (ASX:DXB) gets ready for game day

Our sister company Pitt Street Research published a research update on the Melbourne-based drug developer Dimerix (ASX: DXB). Pitt Street Research used to have a valuation range of between 84…

ByStuart Roberts

Oct 2025

Healthcare Stocks

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech…

ByNick Sundich

Aug 2025

Healthcare Stocks Life Sciences

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug…

ByNick Sundich

May 2025

Biotech Stocks Healthcare Stocks

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this morning! The company already had licensing deals with 2 companies…

ByNick Sundich

Jan 2025

Healthcare Stocks Life Sciences

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing's first. We know this ASX health stock fell 14% on January 8 after…

ByNick Sundich

Nov 2024

Healthcare Stocks

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

Dimerix (ASX:DXB) is one of the few ASX biotechs in the middle of a Phase 3 trial, and it even has data showing the trial is a success. After years…

ByNick Sundich

Aug 2024

Healthcare Stocks

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are…

ByNick Sundich

the Kick-ass Multipurpose WordPress Theme

Shares In Dimerix (ASX:DXB) Fell 40% Today; Not About The Data, But About the Timing

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

Dimerix (ASX:DXB) gets ready for game day

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Stocks in Spotlight

Add Your Heading Text Here